Longitudinal investigation of carriage rates and genotypes of toxigenic *Clostridium difficile* in hepatic cirrhosis patients

Yunbo Chen1*, Hongqin Gu2*, Tao Lv1, Dong Yan1, Qiaomai Xu1, Silan Gu1, Ping Shen1, Jiazheng Quan1, Yunhui Fang1, Lifeng Chen3, Guangyong Ye4 and Lanjuan Li1

1State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China; 2Clinical Laboratory, Hangzhou Third Hospital, Hangzhou, Zhejiang, China; 3Medical Engineering Department, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China and 4Women’s Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China

Abstract

Toxigenic *Clostridium difficile* (*C. difficile*) carriers represent an important source in the transmission of *C. difficile* infection (CDI) during hospitalisation, but its prevalence and mode in patients with hepatic cirrhosis are not well established. We investigated longitudinal changes in carriage rates and strain types of toxigenic *C. difficile* from admission to discharge among hepatic cirrhosis patients. Toxigenic *C. difficile* was detected in 104 (19.8%) of 526 hepatic cirrhosis patients on admission, and the carriage status changed in a portion of patients during hospitalisation. Approximately 56% (58/104) of patients lost the colonisation during their hospital stay. Among the remaining 48 patients who remained positive for toxigenic *C. difficile*, the numbers of patients who were positive at one, two, three and four isolations were 10 (55.6%), three (16.7%), two (11.1%) and three (16.7%), respectively. Twenty-eight patients retained a particular monophyletic strain at multiple isolations. The genotype most frequently identified was the same as that frequently identified in symptomatic CDI patients. A total of 25% (26/104) of patients were diagnosed with CDI during their hospital stay. Conclusions: Colonisation with toxigenic *C. difficile* strains occurs frequently in cirrhosis patients and is a risk factor for CDI.

Introduction

*Clostridium difficile* (*C. difficile*) infection (CDI) is one of leading causes of mortality in the developed world [1] and estimated to be responsible for 10–20% of antibiotic-associated diarrhoea cases including all cases of pseudomembranous colitis [2], resulting in an estimated medical cost of €3 billion per annum among the EU states [3] and $1.5 billion per annum in the USA [4]. It has been accepted that this organism spreads nosocomially and causes outbreaks of CDI in various clinical settings [2]. Infected or colonised patients and contaminated environments constituted potential sources of *C. difficile* [5] in hospital settings. Asymptomatic carriers shed spores into the environment to a lesser extent than CDI patients [6], but because *C. difficile* colonisation is fivefold to 10-fold more common than symptomatic infection [7], they serve as an important reservoir for nosocomial transmission. Nearly 30 years ago, Clabots et al. found that most episodes of nosocomial acquisition of CDI in a study ward were epidemiologically linked to transmission from asymptomatic new admissions [8]. This link was more recently supported by a Canadian study, in which the isolation of *C. difficile*-colonised patients was accompanied by a significantly reduced incidence of hospital-acquired CDI in recent years [9]. It was also reported that asymptomatic colonisation increases the risk of subsequent clinical disease [10]. Approximately 5–15% of patients newly admitted to hospitals carry *C. difficile* in their faeces [10, 11], and it has been reported that one-sixth to one-third of the carriers may develop symptoms [12].

However, there have been no reports of associations between noted involvement of asymptomatic carriage in the transmission of toxigenic *C. difficile* in healthcare facilities and corresponding practice to block the transmission [13], as they have not been a focus of CDI control measures [14]. It is noteworthy that there was a different impression that asymptomatic colonisation with *C. difficile* was associated with a decreased risk of diarrhoea [15].

The carriage and transmission frequencies of *C. difficile* have been studied in an elderly population living in long-term care facilities (LTCFs) [16], as well as in healthy adults aged up to 65 years (median age, 22 years) in Japan [17], many of whom were college students. To the best of our knowledge, there have been no studies of carriage among patients with a
specific disease. For example, there are no reports on liver cirrhotic patients, who are more prone to acquire CDI as a result of disturbed microbiota in the gut, increased hospital visits and antibiotic usage. In this study, we investigated the asymptomatic carriage and genotype of _C. difficile_ in these patients using stool specimens collected from admission to discharge. We determined the frequency of asymptomatic toxigenic _C. difficile_ carriage at admission and at different time points after hospitalisation. We also investigated whether the strains isolated from these patients represented current endemic _C. difficile_ genotypes in China.

**Materials and methods**

**Study design**

During a 6-month period in 2015 (1 May to 31 October), we conducted a cohort study of all patients who provided consent in the Infectious Disease Department of the First Affiliated Hospital, Zhejiang University. On average, there were 168 admissions per ward per month, including 34 admissions that stayed for more than 48 h. Cirrhosis was diagnosed based on previous liver biopsy results, clinical evidence of previous decompensation and laboratory tests, endoscopy and radiological imaging of portal hypertension and/or liver nodularity. Patients were excluded if they: had hepatic carcinoma or other malignancies, had diarrhoea on admission, were discharged within 2 days, were transferred from other wards to the participating wards and were readmitted during this period. Stool samples were collected within 48 h of admission and then weekly during hospitalisation until discharge or diagnosis with CDI.

Written informed consent was obtained from each patient. The study protocols were approved by the Ethical Committee of the First Affiliated Hospital, Zhejiang University School of Medicine.

**Definitions**

Asymptomatic carriage was defined as positivity for toxigenic _C. difficile_ without symptoms of diarrhoea at the time of stool collection [18] or in the first 48 h of admission. If identified in a negative patient after 48 h, nosocomial acquisition was considered. CDI was defined by diarrhoea episodes (≥3 unformed stools in 24 h) occurring at least 48 h after admission, diagnosis with the two-stage algorithms, and negative results for other diarrhoea-causing pathogens including _Salmonella_ spp., _Shigella_ spp., _Vibrio_ spp., _Staphylococcus aureus_ and _Escherichia coli_.

When the patient was documented with _C. difficile_ diarrhoea, caregivers and others were advised to exercise contact precautions, including using gloves, wearing gowns and using chlorhexidine for hand hygiene.

**Isolation of _C. difficile_ from faecal samples and diagnosis of CDI**

The stool samples, including admission and follow-up during hospitalisation, were cultured on cycloserine-cefoxitin-fructose agar in an atmosphere composed of 80% N₂, 10% H₂ and 10% CO₂ at 37 °C for 48 h. A maximum of five colonies was picked from each _C. difficile_-positive plate. Colonies with typical morphology and odour were confirmed as _C. difficile_ by matrix-assisted laser desorption-ionisation mass spectrometry (MALDI-TOF MS, Flexcontrol3.3-microflex).

The two-stage algorithms were used to confirm the microbiological evidence of toxin-producing _C. difficile_ in stools. Only unformed or watery stool samples were detected for _C. difficile_ toxins (Bristol Stool Chart types 5–7) [19]. The protocol of the two-stage algorithms, including glutamate dehydrogenase and toxin A and B detection by enzyme immunoassay (EIA) (Vidas; bio-Mérieux, Marcy-l’Etoile, France), was described previously [20].

**DNA extraction and detection of toxigenic genes**

The isolates of _C. difficile_ were grown on blood agar incubated anaerobically for 48 h. Genomic DNA from the two isolates was extracted using the QiAamp DNA Mini Kit (Qiagen, Hilden, Germany). _TcdA_ and _tcdB_ genes were detected by PCR as described previously [21]. Both binary toxin genes, _cdtA_ and _cdtB_, were detected as described by Stubbs et al. [22].

**Multi-locus sequence typing**

Multi-locus sequence typing (MLST) was performed on all toxigenic strains according to the previously described protocols [23]. The sequence type (ST) was determined according to a combination of alleles identified by comparing the obtained sequences with sequences available in the _C. difficile_ MLST database available at: http://pubmlst.org/cdifficile/.

**Results**

A total of 805 patients were admitted during the study period, and 279 of them were excluded. Included in the evaluation were 1056 faeces samples from 526 patients, of which 104 (19.8%) were positive for toxigenic _C. difficile_ upon admission (Fig. 1). Follow-up was performed on these 104 patients weekly until they were discharged or diagnosed with CDI. Among these 104 patients, 44.2% (46/104) of the patients had at least one toxigenic _C. difficile_-positive at least one time during their hospitalisation and the remainder had only positive at admission. Sixteen ST types were identified among the 104 isolates from admission samples (Table 1). The top four types were ST-54 (18.5%, 19/104), ST-35 (15.4%, 16/104), ST-3 (21.2%, 22/104) and ST-37 (14.4%, 15/104). There were 76 isolates and 17 ST types identified during the follow-up. The top four types were ST-54 (26.3%, 20/76), ST-3 (17.1%, 13/76), ST-35 (11.8%, 9/76) and ST-37 (6.6%, 5/76). ST-15, ST-109, ST-220 and ST-294 were identified on admission and became negative afterwards, while new STs including ST-2, ST-26, ST-48, ST-55 and ST-129 emerged. Continuous colonisation with the same STs was detected in 28 patients (26.9%), while different STs were identified in 18 patients (17.3%) over the course of hospitalisation. Ten STs detected on admission were changed during hospitalisation. ST-35 and ST-37 were most frequently changed to other STs (25% and 26.7%, respectively). Among the 46 patients who remained positive after admission, the percentages who were positive for two, three, four, or more isolations were 29.8% (31/104), 5.8% (6/104) and 8.7% (9/104), respectively. No C. difficile NAP1/BI/027/ST1 or 078 isolates were identified in this study, and no specimens contained two or more different toxin types.

CDI occurred in 25% (26/104) of patients during their hospital stay. The percentages of patients who had two, three and four positive isolations before diagnosis with CDI were 53.8% (14/26), 15.4% (4/26) and 15.4% (4/26), respectively. Three patients...
remained positive for five isolations and one for seven isolations. These four patients were diagnosed with CDI in the last sample. The time between detection of colonised *C. difficile* and CDI diagnosis was 1–2 weeks.

**Discussion**

One uniqueness in this study is the availability of first stool samples taken at or near admission and then the collection of weekly samples afterwards, which allowed us to study *C. difficile* colonisation and infection kinetics. Toxigenic *C. difficile* was detected in 19.8% of hepatic cirrhosis patients on admission. Different colonisation rates have been reported by different studies [10], and several explanations are possible. (1) Different detection methods were employed. Nucleic acid amplification tests were the most sensitive in some studies [24], while toxin EIAs were suboptimal in sensitivity. In this study, stool sample cultures, which are more sensitive than swab cultures, were performed [25]. (2) Various risk factors are associated with asymptomatic *C. difficile* carriage including age, admission from another healthcare facility, overnight hospitalisation within the prior 90 days and exposure to antibiotics in the 90 days prior to admission [26]. Our cirrhosis patients may have had these risk factors for toxigenic *C. difficile* carriage, leading to a higher carriage rate compared with those previously reported [27].

ST-54, ST-35, ST-3 and ST-37 were the most prevalent among admission samples, and these STs were reported as the most common STs causing *C. difficile* infection in China [28–30]. In this study, 25% (26/104) of these patients developed CDI during their hospital stay, and ST-54 and ST-35 were the dominant types identified in these CDI patients [31]. These results were consistent with those of a report that the asymptomatic *C. difficile* carriage rate is similar to the symptomatic positivity rate, implying that CDI in the majority of symptomatic patients was likely derived from *C. difficile* colonisation [15], which represents a significant infection risk. All these reports support the hypothesis that the admission of asymptomatic *C. difficile* colonised patients contributes to sustained *C. difficile* transmission within a ward [32].

In this study, nearly 60% of the patients were positive only in admission samples, suggesting a transient colonisation. As reported in a 6-month follow-up of 18 colonised healthy students, 10 (56%) of them lost the colonisation [17]. Only 46 patients (40%) were positive for multiple isolations in this cohort, comparing eight (44%) of 18 colonised more than once, of whom three (38%) harboured the same strain previously reported [17]. However, there were no reports of colonisation during the follow-up of the hospitalised population. There were patients who showed continuous colonisation of toxigenic *C. difficile* after admission, and thus, hospitalisation may be a risk factor for colonisation in this study. There were three patients who were *C. difficile*-positive three or more times, and the *C. difficile* isolates from each of the three patients were different from the first isolates, but for all isolates, the same isolates were detected in at least two consecutive occasions. These findings suggest that there is a marked variation in the duration of the colonised state and the environment may have been contaminated. In an investigation of repeated exposure from the environment or other colonised individuals, *C. difficile* strains with the same STs were isolated from 28 patients (26.9%) during their hospital stay. These results suggest that cross-transmission of *C. difficile* may be relatively common among colonised individuals, or *C. difficile* may spread from a common source in the work environment.

Our previous study and other reports have shown that carriers of *C. difficile* are significantly more likely to develop diarrhoea during hospitalisation than non-carriers [31, 33]. Asymptomatic carriage identified at admission was a decisive risk factor for symptomatic infection during hospital stay, accounting for about 25% of the patients (26 of 104) who developed CDI during the study. Thus, screening for toxigenic *C. difficile* carriage at admission could predict the likelihood of a later symptomatic CDI, as described in previous studies [10, 14].

Another important finding was with an increasing number of positive isolations, the risk for CDI increased. In this study, of 15 patients who were positive for multiple isolations, 12 developed CDI. This study showed that different types of *C. difficile* influenced the infection. It is important to screen the colonisation of toxigenic *C. difficile* when patients were admitted, especially for those patients who have a higher risk for infection.

On average, it takes 5 days for colonised patients to develop symptoms [32, 34]. In this cohort, symptom development took 1–2 weeks, except in one patient who was diagnosed with CDI after 2 weeks. This was similar to other reports [27, 35].
Table 1. Positive isolations and sequence types from 104 patients with *C. difficile* colonisation and/or infection

| No of Patients | Gender | Age | Isolated on admission | Isolated in week 2 | Isolated in week 3 | Isolated in week 4 | Isolated in week 5 | Isolated in week 6 | Isolated in week 7 | Isolated in week 8 | Diagnosed with CDI |
|----------------|--------|-----|-----------------------|--------------------|-------------------|-------------------|-------------------|-------------------|-------------------|-------------------|------------------|
| P1             | Female | 65  | ST-3                  | ST-3               |                   |                   |                   |                   |                   |                   |                  |
| P2             | Male   | 51  | ST-3                  |                    |                   |                   |                   |                   |                   |                   |                  |
| P3             | Male   | 49  | ST-3                  |                    |                   |                   |                   |                   |                   |                   |                  |
| P4             | Male   | 45  | ST-3                  |                    |                   |                   |                   |                   |                   |                   |                  |
| P5             | Male   | 47  | ST-3                  |                    |                   |                   |                   |                   |                   |                   |                  |
| P6             | Male   | 54  | ST-3                  |                    |                   |                   |                   |                   |                   |                   |                  |
| P7             | Male   | 49  | ST-3                  |                    |                   |                   |                   |                   |                   |                   |                  |
| P8             | Male   | 56  | ST-3                  |                    |                   |                   |                   |                   |                   |                   |                  |
| P9             | Male   | 61  | ST-3                  |                    |                   |                   |                   |                   |                   |                   |                  |
| P10            | Male   | 75  | ST-3                  | ST-3               |                   |                   |                   |                   |                   |                   |                  |
| P11            | Male   | 43  | ST-3                  | ST-3               |                   |                   |                   |                   |                   |                   |                  |
| P12            | Female | 76  | ST-3                  |                    |                   |                   |                   |                   |                   |                   |                  |
| P13            | Female | 52  | ST-3                  |                    | ST-3              |                   |                   |                   |                   |                   |                  |
| P14            | Male   | 22  | ST-3                  |                    |                   |                   |                   |                   |                   |                   |                  |
| P15            | Male   | 59  | ST-3                  |                    |                   |                   |                   |                   |                   |                   |                  |
| P16            | Male   | 75  | ST-3                  | ST-3              | ST-3              | ST-3              |                   |                   |                   |                   |                  |
| P17            | Male   | 39  | ST-3                  |                    |                   |                   |                   |                   |                   |                   |                  |
| P18            | Male   | 46  | ST-3                  | ST-3              |                   |                   |                   |                   |                   |                   |                  |
| P19            | Male   | 35  | ST-3                  |                    |                   |                   |                   |                   |                   |                   |                  |
| P20            | Male   | 30  | ST-3                  | ST-26             |                   |                   |                   |                   |                   |                   |                  |
| P21            | Male   | 56  | ST-3                  |                    |                   |                   |                   |                   |                   |                   |                  |
| P22            | Male   | 55  | ST-3                  | ST-55             |                   |                   |                   |                   |                   |                   |                  |
| P23            | Male   | 59  | ST-6                  | ST-6              |                   |                   |                   |                   |                   |                   |                  |
| P24            | Male   | 51  | ST-8                  |                    |                   |                   |                   |                   |                   |                   |                  |
| P25            | Male   | 65  | ST-8                  | ST-8              |                   |                   |                   |                   |                   |                   |                  |
| P26            | Male   | 53  | ST-8                  |                    |                   |                   |                   |                   |                   |                   |                  |
| P27            | Male   | 32  | ST-8                  |                    |                   |                   |                   |                   |                   |                   | ST-54            |
| P28            | Male   | 43  | ST-8                  |                    |                   |                   |                   |                   |                   |                   |                  |
| P29            | Female | 56  | ST-8                  |                    |                   |                   |                   |                   |                   |                   |                  |
| P30            | Female | 51  | ST-14                 | ST-14             |                   |                   |                   |                   |                   |                   |                  |
| P31            | Male   | 54  | ST-14                 |                    |                   |                   |                   |                   |                   |                   |                  |
| P32            | Male   | 52  | ST-14                 |                    |                   |                   |                   |                   |                   |                   |                  |

Yunbo Chen et al.
|   | Gender | Age | ST-14 | ST-15 | ST-16 | ST-29 | ST-34 | ST-35 | ST-37 | CDI |
|---|--------|-----|-------|-------|-------|-------|-------|-------|-------|-----|
| P33 | Male   | 41  | ST-14 | ST-14 |       |       |       |       |       |     |
| P34 | Male   | 75  | ST-14 |       |       |       |       |       |       |     |
| P35 | Female | 63  | ST-14 |       |       |       |       |       |       |     |
| P36 | Male   | 59  | ST-14 |       |       |       |       |       |       |     |
| P37 | Female | 56  | ST-15 | ST-15 | ST-15 | ST-35 |       |       |       | CDI |
| P38 | Male   | 60  | ST-29 | ST-29 | ST-29 | ST-29 |       |       |       | CDI |
| P39 | Male   | 39  | ST-34 | ST-34 |       |       |       |       |       | CDI |
| P40 | Female | 61  | ST-35 |       |       |       |       |       |       |     |
| P41 | Male   | 42  | ST-35 | ST-35 |       |       |       |       |       | CDI |
| P42 | Male   | 42  | ST-35 | ST-129| ST-129| ST-129|       |       |       |     |
| P43 | Male   | 49  | ST-35 |       |       |       |       |       |       |     |
| P44 | Male   | 54  | ST-35 | ST-35 | ST-35 | ST-37 |       |       |       | CDI |
| P45 | Female | 58  | ST-35 |       | ST-35 |       |       |       |       | CDI |
| P46 | Female | 70  | ST-35 |       |       |       |       |       |       |     |
| P47 | Female | 49  | ST-35 | ST-35 | ST-37 | ST-37 | ST-37 |       |       | CDI |
| P48 | Male   | 64  | ST-35 |       |       | ST-48 |       |       |       |     |
| P49 | Male   | 45  | ST-35 |       |       |       |       |       |       |     |
| P50 | Female | 62  | ST-35 |       |       |       |       |       |       |     |
| P51 | Male   | 66  | ST-35 | ST-35 | ST-35 |       |       |       |       | CDI |
| P52 | Male   | 54  | ST-35 |       |       |       |       |       |       |     |
| P53 | Male   | 47  | ST-35 |       |       |       |       |       |       |     |
| P54 | Male   | 63  | ST-35 |       |       |       |       |       |       |     |
| P55 | Male   | 71  | ST-35 |       |       |       |       |       |       |     |
| P56 | Female | 70  | ST-37 |       |       |       |       |       |       |     |
| P57 | Female | 90  | ST-37 |       |       |       |       |       |       |     |
| P58 | Male   | 49  | ST-37 | ST-2  |       |       |       |       |       |     |
| P59 | Male   | 26  | ST-37 | ST-2  |       |       |       |       |       |     |
| P60 | Male   | 66  | ST-37 |       |       |       |       |       |       |     |
| P61 | Male   | 48  | ST-37 | ST-2  |       |       |       |       |       |     |
| P62 | Female | 55  | ST-37 | ST-3  | ST-3  |       |       |       |       |     |
| P63 | Male   | 50  | ST-37 |       |       |       |       |       |       |     |
| P64 | Male   | 36  | ST-37 |       |       |       |       |       |       |     |
| P65 | Male   | 54  | ST-37 |       |       |       |       |       |       |     |
| P66 | Male   | 60  | ST-37 |       |       |       |       |       |       |     |

(Continued)
| No of Patients | Gender | Age | Isolated on admission | Isolated in week 2 | Isolated in week 3 | Isolated in week 4 | Isolated in week 5 | Isolated in week 6 | Isolated in week 7 | Isolated in week 8 | Diagnosed with CDI |
|---------------|--------|-----|-----------------------|-------------------|-------------------|-------------------|-------------------|-------------------|-------------------|-------------------|------------------|
| P67           | Male   | 68  | ST-37                 |                   |                   |                   |                   |                   |                   |                   | CDI               |
| P68           | Female | 47  | ST-37                 |                   |                   |                   |                   |                   |                   |                   |                  |
| P69           | Male   | 68  | ST-37                 |                   |                   |                   |                   |                   |                   |                   |                  |
| P70           | Male   | 56  | ST-37                 |                   |                   |                   |                   |                   |                   |                   |                  |
| P71           | Male   | 61  | ST-39                 |                   |                   |                   |                   |                   |                   |                   |                  |
| P72           | Male   | 44  | ST-39                 |                   |                   |                   |                   |                   |                   |                   |                  |
| P73           | Female | 67  | ST-39                 |                   |                   |                   |                   |                   |                   |                   |                  |
| P74           | Male   | 65  | ST-39                 | ST-39             | ST-39             | ST-39             |                   |                   |                   |                   | CDI               |
| P75           | Male   | 72  | ST-39                 |                   |                   | ST-54             |                   |                   |                   |                   |                  |
| P76           | Male   | 46  | ST-39                 |                   |                   |                   |                   |                   |                   |                   |                  |
| P77           | Male   | 42  | ST-54                 |                   |                   |                   |                   |                   |                   |                   | CDI               |
| P78           | Male   | 66  | ST-54                 |                   |                   |                   |                   |                   |                   |                   |                  |
| P79           | Male   | 52  | ST-54                 |                   |                   |                   |                   |                   |                   |                   |                  |
| P80           | Male   | 45  | ST-54                 |                   |                   |                   |                   |                   |                   |                   |                  |
| P81           | Male   | 66  | ST-54                 |                   |                   |                   |                   |                   |                   |                   | CDI               |
| P82           | Female | 72  | ST-54                 |                   |                   |                   |                   |                   |                   |                   |                  |
| P83           | Female | 54  | ST-54                 |                   |                   |                   |                   |                   |                   |                   |                  |
| P84           | Male   | 54  | ST-54                 | ST-54             | ST-54             | ST-54             | ST-54             |                   | ST-54             | ST-54             | CDI               |
| P85           | Male   | 40  | ST-54                 | ST-54             | ST-54             |                   |                   |                   |                   |                   |                  |
| P86           | Female | 69  | ST-54                 |                   |                   |                   |                   |                   |                   |                   |                  |
| P87           | Male   | 58  | ST-54                 |                   |                   |                   |                   |                   |                   |                   |                  |
| P88           | Male   | 72  | ST-54                 |                   |                   |                   |                   |                   |                   |                   |                  |
| P89           | Male   | 47  | ST-54                 | ST-54             |                   |                   |                   |                   |                   |                   | CDI               |
| P90           | Male   | 54  | ST-54                 |                   |                   |                   |                   |                   |                   |                   |                  |
| P91           | Male   | 44  | ST-54                 |                   |                   |                   |                   |                   |                   |                   | CDI               |
| P92           | Male   | 49  | ST-54                 |                   |                   |                   |                   |                   |                   |                   |                  |
| P93           | Male   | 42  | ST-54                 |                   |                   |                   |                   |                   |                   |                   |                  |
| P94           | Male   | 74  | ST-54                 |                   |                   |                   |                   |                   |                   |                   |                  |
| P95           | Male   | 39  | ST-54                 |                   |                   |                   |                   |                   |                   |                   |                  |
| P96           | Male   | 43  | ST-81                 |                   |                   |                   |                   |                   |                   |                   | CDI               |
| P97           | Male   | 59  | ST-81                 |                   |                   |                   |                   |                   |                   |                   |                  |
| P98           | Male   | 46  | ST-81                 |                   |                   |                   |                   |                   |                   |                   | CDI               |
We note some limitations in this study. First, we tried to collect samples from patients within 2 days after admission. However, some patients were excluded because they had no stools within 2 days, reducing the number of patients with bias for the colonisation rate. Second, we did not take into consideration the therapy, especially antibiotic treatment during hospital stay, which is expected to have an impact on the colonisation of *C. difficile*. Third, we did not re-examine the patients who were negative for *C. difficile* at admission, and these patients may colonise *C. difficile* during their hospitalisation. Finally, we cannot be certain that the individuals who were colonised with toxigenic *C. difficile* on admission to the LTCF acquired colonisation during their hospital stay; it was possible that they carried *C. difficile* at the time of admission to the hospital.

**Conclusions**

Toxigenic *C. difficile* was detected in 104 (19.8%) of 526 hepatic cirrhosis patients on admission. Moreover, the carriage status changed in a portion of patients, whereas 55.8% (58/104) of patients lost the colonisation of toxigenic *C. difficile* during their hospital stay. Among the remaining 48 patients who remained positive for toxigenic *C. difficile*, 25% (26/104) were diagnosed with CDI during hospital stay. This study highlights the importance of identifying asymptomatic *C. difficile* carriers among hepatic cirrhosis patients on admission.

**Author ORCIDs.**

Lanjuan Li, 0000-0001-6945-0593.

**Acknowledgements.** This study was partially funded by grants from the National Basic Research Program of China (973 program, No. 2015CB554201).

**References**

1. Daneman N *et al.* (2015) The association of hospital prevention processes and patient risk factors with the risk of *Clostridium difficile* infection: a population-based cohort study. *BMJ Quality & Safety* 24, 435–443.
2. Kelly CP, Pothoulakis C and LaMont JT (1994) *Clostridium difficile* colitis. *The New England Journal of Medicine* 330, 257–262.
3. Kuijper EJ *et al.* (2006) Emergence of *Clostridium difficile*-associated disease in North America and Europe. *Clinical Microbiology and Infection* 12 (suppl. 6), 2–18.
4. Lefller DA and Lamont JT (2015) *Clostridium difficile* Infection. *The New England Journal of Medicine* 373, 287–288.
5. Gerding DN *et al.* (1986) *Clostridium difficile* – diarrhea and colitis in adults. A prospective case-controlled epidemiologic study. *Archives of Internal Medicine* 146, 95–100.
6. Guerrero DM *et al.* (2013) Asymptomatic carriage of toxigenic *Clostridium difficile* by hospitalized patients. *The Journal of Hospital Infection* 85, 155–158.
7. Polage CR, Solnick JV and Cohen SH (2012) Nosocomial diarrhea: evaluation and treatment of causes other than *Clostridium difficile*. *Clinical Infectious Diseases* 55, 982–989.
8. Clabots CR *et al.* (1992) Acquisition of *Clostridium difficile* by hospitalized patients: evidence for colonized new admissions as a source of infection. *The Journal of Infectious Diseases* 166, 561–567.
9. Longtin Y *et al.* (2016) Effect of detecting and isolating *Clostridium difficile* carriers at hospital admission on the incidence of *C difficile* infections: a quasi-experimental controlled study. *JAMA Internal Medicine* 176, 796–804.
10. Zacharioudakis IM *et al.* (2015) Colonization with toxigenic *C. difficile* upon hospital admission, and risk of infection: a systematic review and meta-analysis. *The American Journal of Gastroenterology* 110, 381–390, quiz 391.
11. Leekha S et al. (2013) Asymptomatic Clostridium difficile colonization in a tertiary care hospital: admission prevalence and risk factors. American Journal of Infection Control 41, 390–393.

12. Hung YP et al. (2012) Impact of toxigenic Clostridium difficile colonization and infection among hospitalized adults at a district hospital in southern Taiwan. PLoS ONE 7, e42415.

13. Donskey CJ, Kundrapu S and Deshpande A (2015) Colonization versus carriage of Clostridium difficile. Infectious Disease Clinics of North America 29, 13–28.

14. Curry SR et al. (2013) Use of multilocus variable number of tandem repeats analysis genotyping to determine the role of asymptomatic carriers in Clostridium difficile transmission. Clinical Infectious Diseases 57, 1094–1102.

15. Truong C et al. (2017) Clostridium difficile rates in asymptomatic and symptomatic hospitalized patients using nucleic acid testing. Diagnostic Microbiology and Infectious Disease 87, 365–370.

16. Rivera EV and Woods S (2003) Prevalence of asymptomatic Clostridium difficile colonization in a nursing home population: a cross-sectional study. The Journal of Gender-Specific Medicine 6, 27–30.

17. Ozaki E et al. (2004) Clostridium difficile colonization in healthy adults: transient colonization and correlation with enterococcal colonization. Journal of Medical Microbiology 53, 167–172.

18. Kelly SG et al. (2016) Inappropriate Clostridium difficile testing and consequent overtreatment and inaccurate publicly reported metrics. Infection Control and Hospital Epidemiology 37, 1395–1400.

19. Lewis SJ and Heaton KW (1997) Stool form scale as a useful guide to intestinal transit time. Scandivian Journal of Gastroenterology 32, 920–924.

20. Shin BM et al. (2016) Evaluation of the VIDAS glutamate dehydrogenase assay for the detection of Clostridium difficile. Anaerobe 40, 68–72.

21. Kato H et al. (1998) Identification of toxin A-negative, toxin B-positive Clostridium difficile by PCR. Journal of Clinical Microbiology 36, 2178–2182.

22. Stubbs S et al. (2000) Production of actin-specific ADP-ribosyltransferase (binary toxin) by strains of Clostridium difficile. FEMS Microbiology Letters 186, 307–312.

23. Griffiths D et al. (2010) Multilocus sequence typing of Clostridium difficile. Journal of Clinical Microbiology 48, 770–778.

24. Gateau C et al. (2017) How to: Diagnose infection caused by Clostridium difficile. Clinical Microbiology and Infection 24, 463–468.

25. Bassis CM et al. (2017) Comparison of stool versus rectal swab samples and storage conditions on bacterial community profiles. BMC Microbiology 17, 78.

26. Kong LY et al. (2015) Predictors of asymptomatic Clostridium difficile colonization on hospital admission. American Journal of Infection Control 43, 248–253.

27. Loo VG et al. (2011) Host and pathogen factors for Clostridium difficile infection and colonization. The New England Journal of Medicine 365, 1693–1703.

28. Chen YB et al. (2017) Molecular epidemiology and antimicrobial susceptibility of Clostridium difficile isolated from hospitals during a 4-year period in China. Journal of Medical Microbiology. 67, 52–59.

29. Gao Q et al. (2016) Toxin profiles, PCR ribotypes and resistance patterns of Clostridium difficile: a multicentre study in China, 2012–2013. International Journal of Antimicrobial Agents 48, 736–739.

30. Wang R et al. (2017) Molecular epidemiology and antimicrobial susceptibility of Clostridium difficile isolated from the Chinese People’s Liberation Army General Hospital in China. International Journal of Infectious Diseases 67, 86–91.

31. Yan D et al. (2017) Clostridium difficile colonization and infection in patients with hepatic cirrhosis. Journal of Medical Microbiology 66, 1483–1488.

32. Lanzas C et al. (2011) Epidemiological model for Clostridium difficile transmission in healthcare settings. Infection Control and Hospital Epidemiology 32, 553–561.

33. Kagan S et al. (2017) The risk for Clostridium difficile colitis during hospitalization in asymptomatic carriers. The Journal of Hospital Infection 95, 442–443.

34. Yakob L et al. (2014) Assessing control bundles for Clostridium difficile: a review and mathematical model. Emerging Microbes & Infections 3, e43.

35. Shim JK et al. (1998) Primary symptomless colonization by Clostridium difficile and decreased risk of subsequent diarrhoea. Lancet 351, 633–636.